Julia Hauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julia Hauer has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Arndt Borkhardt
Children's University Hospital Düsseldorf, Department for Hematology and Oncology, Heinrich‐Heine‐University, Duesseldorf, Germany
1 shared publication- Arndt Borkhardt
Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty Heinrich Heine University Düsseldorf Düsseldorf Germany
1 shared publication Friedhelm R. Schuster
Pediatric Hematology & Oncology, LMU Munich, Dr. von Haunersches Children's Hospital, Munich, Germany
1 shared publication- Friedhelm R. Schuster
Clinic of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
1 shared publication - Hans-Jochem Kolb
Klinikum Grosshadern, Med. Klinik III, München, Germany
1 shared publication Hans‐Jochem Kolb
Jose Carreras Bone Marrow Transplantation Unit, III. Medical Clinic, LMU Munich, Munich, Germany
1 shared publication
Latest Publications
- Open Access
- 6 July 2013
- Published by Wiley in British Journal of Haematology
- Vol. 162 (6) , 802-807
Anti‐leukaemic activity of a novel haploidentical‐transplantation approach employing unmanipulated bone marrow followed by CD6‐depleted peripheral blood stem cells in children with refractory/relapsed acute leukaemia
The treatment outcome of children with refractory acute leukaemia or relapse post‐stem cell transplantation is dismal. We report 10 children (non‐remission n = 7) who underwent a new haploidentical transplant approach utilizing unmanipulated bone marrow followed by CD6‐depleted peripheral blood stem cells. Nine patients had successful engraftment and no evidence of leukaemia. Acute and chronic graft‐versus‐host‐disease was observed in five and three patients, respectively; two patients died of treatment‐related toxicity. Seven patients relapsed after 7 (range 3–34) months, however two patients are alive at 6·5 and 7·0 years. This approach provides anti‐leukaemic activity even in heavily pre‐treated children but long‐term disease control requires further intervention.
- 6 July 2013
- Published by Wiley in British Journal of Haematology
- Vol. 162 (6) , 802-807
Open AccessAnti‐leukaemic activity of a novel haploidentical‐transplantation approach employing unmanipulated bone marrow followed by CD6‐depleted peripheral blood stem cells in children with refractory/relapsed acute leukaemia
The treatment outcome of children with refractory acute leukaemia or relapse post‐stem cell transplantation is dismal. We report 10 children (non‐remission n = 7) who underwent a new haploidentical transplant approach utilizing unmanipulated bone marrow followed by CD6‐depleted peripheral blood stem cells. Nine patients had successful engraftment and no evidence of leukaemia. Acute and chronic graft‐versus‐host‐disease was observed in five and three patients, respectively; two patients died of treatment‐related toxicity. Seven patients relapsed after 7 (range 3–34) months, however two patients are alive at 6·5 and 7·0 years. This approach provides anti‐leukaemic activity even in heavily pre‐treated children but long‐term disease control requires further intervention.
- 24 October 2007
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (4) , 921-923
Graft versus leukemia effect after haploidentical HSCT in a MLL‐negative infant AML with HLXB9/ETV6 rearrangement
Recently published data show an extremely poor survival of infants with AML and HLXB9/ETV6 rearrangement which is the fusion, resulting from the translocation t(7;12)(q36;p13). None of the patients reported survived a period of 3 years, including four patients who have received allogeneic hematopoietic stem cell transplantation (HSCT). Herein, we report the clinical course of an 8‐month‐old patient with acute myeloid leukemia, M2 subtype and with a HLXB9/TEL rearrangement. The patient received a haploidentical HSCT in relapse situation without any prior re‐induction. The patient became MRD‐negative over a period of 53 days after HSCT. This case reinforces the potential benefit of a graft‐versus‐leukemia effect in the haploidentical setting even in chemoresistant myeloid leukemias with poor‐prognosis molecular features. Pediatr Blood Cancer 2008;50:921–923.
- 24 October 2007
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (4) , 921-923
Graft versus leukemia effect after haploidentical HSCT in a MLL‐negative infant AML with HLXB9/ETV6 rearrangement
Recently published data show an extremely poor survival of infants with AML and HLXB9/ETV6 rearrangement which is the fusion, resulting from the translocation t(7;12)(q36;p13). None of the patients reported survived a period of 3 years, including four patients who have received allogeneic hematopoietic stem cell transplantation (HSCT). Herein, we report the clinical course of an 8‐month‐old patient with acute myeloid leukemia, M2 subtype and with a HLXB9/TEL rearrangement. The patient received a haploidentical HSCT in relapse situation without any prior re‐induction. The patient became MRD‐negative over a period of 53 days after HSCT. This case reinforces the potential benefit of a graft‐versus‐leukemia effect in the haploidentical setting even in chemoresistant myeloid leukemias with poor‐prognosis molecular features. Pediatr Blood Cancer 2008;50:921–923.